We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Wearable Multiplex Biosensors Could Revolutionize COPD Management

By HospiMedica International staff writers
Posted on 25 Apr 2024

Chronic obstructive pulmonary disease (COPD) ranks as the third leading cause of death worldwide. More...

Acute exacerbations of COPD (AECOPD), which are often triggered by lung infections, accelerate the disease's progression and create significant challenges for both patients and healthcare systems. These exacerbations increase breathlessness, typically occurring several days post-infection, and often require antibiotic treatment or hospitalization. Predicting AECOPD is complex, and to address this, a new research project is focusing on developing wearable multiplex biosensors that can monitor exacerbation risk in COPD patients.

This research is prompted by findings that indicators of infection can be detected in the blood of AECOPD patients before symptoms appear, specifically through inflammatory signaling molecules. Building on their prior work, a collaborative team from The Lundquist Institute (Torrance, CA, USA) has developed a wearable nanoengineered biosensor capable of real-time, non-invasive monitoring of C-reactive protein (CRP) in sweat, which is associated with blood-borne inflammatory responses. Their ongoing research aims to identify molecules in sweat that could predict future AECOPD, paving the way for real-time, on-body monitoring without the need for frequent blood draws.

The ultimate objective of this project is to create a wearable system that can provide early warnings of AECOPD, allowing for earlier intervention in the exacerbation process to potentially reduce patient morbidity and mortality, hospitalization, and overall healthcare utilization. The proposed sensor could revolutionize the management of COPD as well as impact healthcare by integrating wearable electronics into routine care. This could enable a shift towards continuous, non-invasive monitoring for improved health outcomes.


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.